Edition:
United States

Making an Ebola vaccine

Share Slideshow

Laboratory technicians of the company Icon Genetics prepare proteins from tobacco plants (Nicotiana benthamiana) for weighing in a laboratory in Halle, Germany August 14, 2014. Icon Genetics GmbH, a German biopharma firm, is helping in the fight against the deadly virus Ebola, by creating antibodies needed for the experimental drug known as ZMapp. REUTERS/Axel Schmidt

Laboratory technicians of the company Icon Genetics prepare proteins from tobacco plants (Nicotiana benthamiana) for weighing in a laboratory in Halle, Germany August 14, 2014. Icon Genetics GmbH, a German biopharma firm, is helping in the fight against the deadly virus Ebola, by creating antibodies needed for the experimental drug known as ZMapp. REUTERS/Axel Schmidt
Close
1 / 12

A laboratory technician at Icon Genetics prepares proteins from tobacco plants for weighing in a laboratory in Halle, August 14, 2014. Scientists at the company have created so-called vectors - DNA used to make plants create antibodies - which are put into bacteria and then transferred into tobacco plants, or nicotiana benthamiana. REUTERS/Axel Schmidt

A laboratory technician at Icon Genetics prepares proteins from tobacco plants for weighing in a laboratory in Halle, August 14, 2014. Scientists at the company have created so-called vectors - DNA used to make plants create antibodies - which are put into bacteria and then transferred into tobacco plants, or nicotiana benthamiana. REUTERS/Axel Schmidt
Close
2 / 12

A tobacco plant is pictured in a laboratory at Icon Genetic in Halle, August 14, 2014. During a week's incubation period in a greenhouse, the plants produce antibodies for the Ebola virus. These antibodies are then extracted from the plant and the waste plant material is discarded. The antibodies can then be used in the drug Zmapp. REUTERS/Axel Schmidt

A tobacco plant is pictured in a laboratory at Icon Genetic in Halle, August 14, 2014. During a week's incubation period in a greenhouse, the plants produce antibodies for the Ebola virus. These antibodies are then extracted from the plant and the waste plant material is discarded. The antibodies can then be used in the drug Zmapp. REUTERS/Axel Schmidt
Close
3 / 12

Victor Klimyuk, COO of Icon Genetics inspects tobacco plants in a laboratory in Halle, August 14, 2014. Klimyuk says the process can be used for fighting many different viruses or illnesses and that it is practical because it can be scaled up easily. REUTERS/Axel Schmidt

Victor Klimyuk, COO of Icon Genetics inspects tobacco plants in a laboratory in Halle, August 14, 2014. Klimyuk says the process can be used for fighting many different viruses or illnesses and that it is practical because it can be scaled up easily. REUTERS/Axel Schmidt
Close
4 / 12

Laboratory technicians at Icon Genetics prepare tobacco plants for drying in a laboratory in Halle, August 14, 2014. There are no licensed treatments or vaccines for Ebola, a contagious hemorrhagic disease, but several biotech companies and research teams have been working on potential drugs. REUTERS/Axel Schmidt

Laboratory technicians at Icon Genetics prepare tobacco plants for drying in a laboratory in Halle, August 14, 2014. There are no licensed treatments or vaccines for Ebola, a contagious hemorrhagic disease, but several biotech companies and research teams have been working on potential drugs. REUTERS/Axel Schmidt
Close
5 / 12

Victor Klimyuk, COO of Icon Genetics, speaks during an interview in a laboratory in Halle, August 14, 2014. So far only 10-12 doses of ZMapp have been made. REUTERS/Axel Schmidt

Victor Klimyuk, COO of Icon Genetics, speaks during an interview in a laboratory in Halle, August 14, 2014. So far only 10-12 doses of ZMapp have been made. REUTERS/Axel Schmidt
Close
6 / 12

A sign is placed on a greenhouse with tobacco plants at Icon Genetic in Halle, August 14, 2014. The WHO's panel of medical ethicists said several experimental drugs had passed the laboratory and animal study phases of development and should be fast-tracked into clinical trials and made available for compassionate use. REUTERS/Axel Schmidt

A sign is placed on a greenhouse with tobacco plants at Icon Genetic in Halle, August 14, 2014. The WHO's panel of medical ethicists said several experimental drugs had passed the laboratory and animal study phases of development and should be fast-tracked into clinical trials and made available for compassionate use. REUTERS/Axel Schmidt
Close
7 / 12

A tobacco plant is pictured in a laboratory at Icon Genetic in Halle, August 14, 2014. Icon Genetics COO Victor Klimyuk says: "Our part is that we provided our colleagues from Mapp Biopharmaceuticals [and] also from Kentucky Bioprocessing, which is involved in vaccine manufacturing, with our production platform that was developed here at the Icon Genetics site here in Germany, Halle." REUTERS/Axel Schmidt

A tobacco plant is pictured in a laboratory at Icon Genetic in Halle, August 14, 2014. Icon Genetics COO Victor Klimyuk says: "Our part is that we provided our colleagues from Mapp Biopharmaceuticals [and] also from Kentucky Bioprocessing, which is involved in vaccine manufacturing, with our production platform that was developed here at the Icon Genetics site here in Germany, Halle." REUTERS/Axel Schmidt
Close
8 / 12

A laboratory technician prepares proteins from tobacco plants for weighing in a laboratory in Halle, August 14, 2014. REUTERS/Axel Schmidt

A laboratory technician prepares proteins from tobacco plants for weighing in a laboratory in Halle, August 14, 2014. REUTERS/Axel Schmidt
Close
9 / 12

Victor Klimyuk, COO of Icon Genetics, speaks during an interview in a laboratory in Halle, August 14, 2014. Klimyuk said he and his colleagues were glad that their work was going towards helping fight the virus. "We are glad to do whatever we can do to support our colleagues to address this problem which is currently existing and I think that was very good decision of the WHO to allow this vaccine to be used even before it went...more

Victor Klimyuk, COO of Icon Genetics, speaks during an interview in a laboratory in Halle, August 14, 2014. Klimyuk said he and his colleagues were glad that their work was going towards helping fight the virus. "We are glad to do whatever we can do to support our colleagues to address this problem which is currently existing and I think that was very good decision of the WHO to allow this vaccine to be used even before it went through all necessary clinical trials because you have to balance a threat: what is more risk? To treat this illness or to let people die," he said. REUTERS/Axel Schmidt
Close
10 / 12

A sign at Icon Genetics is pictured in Halle, August 14, 2014. REUTERS/Axel Schmidt

A sign at Icon Genetics is pictured in Halle, August 14, 2014. REUTERS/Axel Schmidt
Close
11 / 12

Victor Klimyuk, COO of Icon Genetics, inspects tobacco plants in a laboratory in Halle, August 14, 2014. REUTERS/Axel Schmidt

Victor Klimyuk, COO of Icon Genetics, inspects tobacco plants in a laboratory in Halle, August 14, 2014. REUTERS/Axel Schmidt
Close
12 / 12

All Collections

Sandy Hook school replaced

Friday, July 29, 2016

All Collections

Rio's Olympic security

Friday, July 29, 2016

All Collections

Colombiamoda fashion

Friday, July 29, 2016

All Collections

Turkey's "Traitors' Cemetery"

Friday, July 29, 2016

All Collections

Key moments at the DNC

Friday, July 29, 2016

All Collections

Protests outside the DNC

Friday, July 29, 2016

All Collections

Pope visits Auschwitz

Friday, July 29, 2016

All Collections

Final night at DNC

Friday, July 29, 2016